¾Ý½¡¿µÊ±±¨2ÔÂ14ÈÕ±¨µÀ£¬Ò½ÔºÅíÖ¾ÓÂÍŶÓÕýÔÚ½øÐдó¼ÁÁ¿Î¬ÉúËØCÖÎÁÆйڷÎÑ×ÁÙ´²ÊÔÑ飬άÉúËØC»ò¿ÉÓÃÓÚÖÎÁÆйڷÎÑס£
ÅíÖ¾Ó½ÌÊÚ½éÉÜ£¬Ä¿Ç°ËûÃÇÁÙ´²ÊÔÑé²ÉÓõÄάÉúËØC¼ÁÁ¿ÊÇ24g£¬Ã¿Î»»¼ÕßÒ»ÌìÓÃÁ½´Î£¬Ã¿´Î12g£¬¶ÔÓÚΣÖز¡È˿ɲÉÓþ²Âö×¢ÉäάÉúËØC£¬ÇáÖ¢²¡ÈËÔò¿É¿Ú·þ¡£
¾ÝÁ˽⣬¸ÃÁÙ´²ÊÔÑé½üÈÕÒÑÔÚÃÀ¹úÁÙ´²ÊÔÑéClinicaltrials.govÍøÕ¾ÉϵǼǡ£
£¨À´Ô´£ºClinicaltrials.gov£©
ÄÇôÎÊÌâ¾ÍÀ´ÁË£¬ÔÚÎÒÃÇÆÕͨÀÏ°ÙÐÕµÄÈÏÖªÀïÃ棬ֻÌý¹ýάÉúËØCÓп¹Ñõ»¯×÷Óã¬ÄÇËüÓÃÓÚÖÎÁÆйڲ¡¶¾·ÎÑ×µÄÒ©Àí×÷ÓûúÖÆÊÇʲô£¿Ó÷¨ÓÃÁ¿£¿ÁÆЧÒÔ¼°°²È«ÐÔÈçºÎ£¿¶ÔÓÚûÓÐйڸÐȾµÄÈË£¬ÄÜ·ñͨ¹ý²¹³äάÉúËØCÀ´Æðµ½Ô¤·À×÷ÓûòÔöÇ¿ÃâÒßÁ¦×÷Óã¿´ø×ÅÕ⼸¸öÎÊÌ⣬ҩʦ²éÔÄÁËÏà¹Ø×ÊÁÏÎÄÏ×£¬Ò»ÆðÀ´¿´¿´°É¡£
1.¹ØÓÚάÉúËØC£¨VitC£©VitCÓֳƿ¹»µÑªËᣬÊÇË®ÈÜÐÔάÉúËØ£¬²ÎÓë¶àÖÖÎïÖʳɷֵĺϳÉÓë´úл¹ý³Ì£¬ÊǽºÔµ°°×¡¢Èⶾ¼î¡¢Éñ¾µÝÖʵÈÉúÎïºÏ³ÉÖв»¿É»òȱµÄÒ»²¿·Ö¡£ÔÚС³¦ÖÐͨ¹ýÄÆÀë×ÓµÄÒÀÀµÐÔVitCתÔËÌå(SVCTl)±»ÎüÊÕ£¬¾ÉöÔàÅÅй¡£ÈËÌå²»ÄÜ×ÔÉíºÏ³ÉVitC£¬Òò´ËÐèÒª´ÓʳÎïÖж¨ÆÚ×ãÁ¿ÉãÈë¡£VitCÔÚѪÇåÖеÄÕý³£·¶Î§ÊÇ40-60¦Ìmol/L£¬µÍÓÚ11¦Ìmol/LÌáʾάÉúËØȱ·¦¡£
ÃÀ¹úIOMºÍÉÅʳ²¹³ä¼Á°ì¹«ÊÒÌá³öάÉúËØC¿ÉÄÍÊÜ×î¸ßÉãÈëÁ¿(TolerableUpperIntakeLevels,UL)Ϊ£ºmg/day£¬ÕâһˮƽָµÄÊÇÔÚÆÕͨÈËȺÖв»Ì«¿ÉÄܵ¼Ö²»Á¼½¡¿µ·´Ó¦µÄ×î´óÿÈÕ¼ÁÁ¿¡£
2.ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÓëVitCÐÂÐ͹Ú×´²¡¶¾·ÎÑ×(CoronavirusDisease£¬COVID-19£¬¼ò³ÆйڷÎÑ×)£¬Êµ¼ÊÊÇÒ»ÖÖ×ÔÏÞÐÔ¼²²¡¡£
×ÔÏÞÐÔ¼²²¡ÊÇָһЩÌØÊâµÄ²¡¶¾¸ÐȾ¼°×ÔÉíÃâÒßÐÔ¼²²¡µÈ£¬Í¨¹ýÈËÌåµÄ×ÔÉíÃâÒßµ÷½Ú£¬Äܹ»Èü²²¡¿µ¸´È¬Óú¡£ÕâЩ³£¼ûµÄ¼²²¡ÓкôÎüµÀºÏ°û²¡¶¾·ÎÑ×£¬±Ç²¡¶¾¡¢ÏÙ²¡¶¾¡¢¹Ú×´²¡¶¾¡¢Á÷¸Ð²¡¶¾ºÍ¸±Á÷¸Ð²¡¶¾£¬Ò²°üÀ¨Ä¿Ç°Á÷ÐеÄÐÂÐ͹Ú×´²¡¶¾·ÎÑ×£¬ÁÙ´²É϶àÒÔ¶ÔÖ¢¡¢Ö§³ÖÖÎÁÆΪÖ÷¡£
Ä¿Ç°£¬ÔÚ¡¶ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÕïÁÆ·½°¸£¨ÊÔÐеÚÆ߰棩¡·[1]²¢Î´Ìá¼°¿ÉÒÔÓÃVitCÖÎÁÆ¡£µ«ÔÚ¡¶ÖØÖ¢ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×»¼ÕßÓªÑøÖ§³ÖÖÎÁƵÄר¼Ò½¨Òé¡·[2]ÖÐÌá³ö£¬ÔÚÖØÖ¢¼±ÐÔºôÎüË¥½ß»¼ÕßµÄÖÎÁƹý³ÌÖУ¬ÓÉÓÚ»¼Õß×ÔÉíÉãÈëVitC¼õÉÙÒÔ¼°Ñõ»¯Ó¦¼¤·´Ó¦Ôö¼Ó£¬Ôö¼ÓVitCµÄ¸øÓèÁ¿ÖÁ6g/d¿Éʹ»¼Õß»ñÒæ[3]¡£Ò²¾ÍÊÇ˵ÔÚÇáÖ¢»¼Õß²¢Î´ÍƼöʹÓÃάÉúËØC£¬Ö»ÓÐÖØÖ¢»¼Õß¿É¿¼ÂÇÓèÒÔάÉúËØC6g/d¡£ÔÚCOVID-19¸ÐȾµÄ»¼ÕßÖУ¬²¿·Ö»¼Õß²¡Çé¼±¾ç¶ñ»¯£¬ÊÇÓÉÓÚÌåÄÚ±¬·¢µÄÑ×Ö¢·ç±©£¨Ï¸°ûÒò×ӷ籩£©µ¼Ö£¬Ï¸°ûÒò×ӷ籩¾ö¶¨·¢ÉúARDSµÄÖØÐÍCOVID-19»¼ÕßÁÙ´²½ø³Ì£¬ÓëΣÖØÐÍCOVID-19»¼Õß·ÎÍâ¶àÆ÷¹Ù¹¦ÄÜË¥½ßÏà¹Ø¡£ÎªÁË·ÀÖÎϸ°ûÒò×ӷ籩£¬ÔÚ¡¶ÉϺ£ÊйÚ×´²¡¶¾²¡×ۺϾÈÖÎר¼Ò¹²Ê¶¡·[4]¼°¡¶ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÁÙ´²ºÏÀíÓÃҩר¼Ò¹²Ê¶£¨µÚÈý°æ£©¡·[5]Ìáµ½µÄÖÎÁÆÒ©Îï¾ùÓдó¼ÁÁ¿Î¬ÉúËØC£ºÎ¬ÉúËØCÿÌì¡«mg/kg£¬¾²ÂöµÎ×¢£¬³ÖÐøʹÓÃʱ¼äÒÔÑõºÏÖ¸ÊýÏÔÖø¸ÄÉÆΪĿ±ê¡£
3.VitCÖÎÁÆÖØÖ¢²¡¶¾¸ÐȾ¿ÉÄܵĻúÖÆ£¨1£©´óÁ¿µÄÑо¿±íÃ÷£¬ÔÚ¼±ÐÔ¼²²¡¡¢ÄÚ¶¾ËØѪ֢ºÍŧ¶¾Ö¢¿ÉÒÔµ¼ÖÂVitC¿ìËÙȱ·¦£¬ÆäÌصãÊÇѪÇåºÍϸ°ûÄÚάÉúËØˮƽ¾ù½ÏµÍ[6-7]¡£ÖØÖ¢¸ÐȾ»¼ÕßÓÉÓÚÑõ»¯£¨´úлÏûºÄ£©Ôö¼Ó£¬ÎüÊÕ¼õÉٺ;ÄòÒº¶ªÊ§Ôö¼Ó£¬Òò´ËÐèÒªÍâÔ´ÐÔ²¹³äVitC¡£
£¨2£©¿¹Ñõ»¯×÷ÓÃÊ×ÏÈVitCͨ¹ýÒÖÖÆ΢Ѫ¹ÜÄÚƤϸ°û³¬Ñõ»¯ÎïµÄ±í´ï£¬¼õÉÙÄÚƤÑõ»¯Ó¦¼¤£¬¸ÄÉÆÄÚƤ¹¦ÄÜÕÏ°£¬¸ÄÉÆ΢Ѫ¹ÜѪÁ÷[8]¡£
£¨3£©¿¹Ñ××÷ÓÃÓж¯ÎïʵÑé±íÃ÷²¹³äVitCÄܸÄÉƸ¹Ç»¸ÐȾºó»úÌåµÄ¿¹Ñõ»¯ÄÜÁ¦£¬¼õÇá¹ýÑõ»¯ËðÉË£¬Ã÷ÏÔÌá¸ß¼±ÐÔÑ×Ö¢ÆÚСÊóµÄÉú´æÂÊ[9]¡£ÌåÍâÅàÑø΢Ѫ¹ÜÄÚƤϸ°ûÑо¿·¢ÏÖ£¬¦Ìmol/LµÄVitC¿É×î´ó³Ì¶ÈµØÒÖÖÆϸ¾úµÄ¸´ÖÆ¡£
£¨4£©ÃâÒßµ÷½Ú×÷ÓôÓÃâÒßѧ½Ç¶È·ÖÎö£¬VitC¿ÉÌáÉýÁÜ°Íϸ°ûµÄÔöÖ³ÄÜÁ¦£¬´Ù½øÍâÖÜѪCD8+¼ÇÒäÐÔTϸ°ûÔöÖ³¡£VitCÌá¸ßÁËŧ¶¾Ö¢Ð¡ÊóµÄϸ°ûÃâÒߣ¬Ã÷ÏÔÒÖÖƵ÷½ÚÐÔTϸ°ûµÄ¸ºÐÔÃâÒßµ÷½Ú×÷Óã¬ÇÒŧ¶¾Ö¢Ð¡ÊóµÄÔ¤ºóºÍŧ¶¾Ö¢ËùÖµÄÆ÷¹Ù¹¦ÄÜÕÏ°¾ùÃ÷ÏÔÌá¸ß[10]¡£´ËÍ⣬VitC»¹¿É´Ì¼¤¸ÉÈÅËصIJúÉú£¬Ôö¼ÓÖÐÐÔÁ£Ï¸°ûµÄÍÌÊɺÍÑõ»¯Çå³ýÄÜÁ¦£¬´Ù½øÁÜ°Íϸ°ûÔöÖ³£¬´ïµ½ÔöÇ¿»úÌåÃâÒß¹¦ÄܵÄЧ¹û[11]¡£
³ýÁËÕâЩÌåÍâÊÔÑ飬ҲÓдóÁ¿µÄÁÙ´²ÊÔÑéÑо¿·¢ÏÖ£¬ÔÚΣÖز¡ÈËÖе¥¶ÀʹÓø߼ÁÁ¿VitC£¬»òÁªºÏÆäËûÒ©ÎïÀýÈçάÉúËØE£¬»òÎø¡¢Ð¿ºÍάÉúËØB£¬ÄܽµµÍ·Î²¡·¢²¡Âʼ°Æ÷¹Ù¹¦ÄÜË¥½ß£¬¼õÉÙ»úеͨÆøÌìÊýºÍËõ¶ÌÖØÖ¢¼à»¤ÊÒºÍ/»òסԺ¡£
4.VitCµÄ¼ÁÁ¿¼°°²È«ÐÔÔÚÒ½ÔºÅíÖ¾ÓÂÍŶӽøÐдó¼ÁÁ¿VitCÖÎÁÆйڷÎÑ×ÁÙ´²ÊÔÑéÖУ¬²ÉÓõÄVitC¼ÁÁ¿ÊÇ24g£¬Ã¿Î»»¼ÕßÒ»ÌìÓÃÁ½´Î£¬Ã¿´Î12g¡£¶øר¼Ò¹²Ê¶ÀïÃæÌá¼°µÄ¼ÁÁ¿Îª6g/d¡£¹ØÓÚάÉúËصÄʹÓüÁÁ¿£¬Ïà¹ØÎÄÏ×±¨¸æ´Ó2-24g²»µÈ¡£ÓÐÑо¿±íÃ÷£¬ÔÚΣÖØÖ¢»¼ÕßÖУ¬ÓÉÓÚѪÇåÖÐάÉúËØCÌ«µÍ³£³£¼ì²â²»µ½£¬¿Ú·þ¼ÁÁ¿mgµÄVitC¼ÁÁ¿²»Äָܻ´µ½Õý³£Ë®Æ½(40-60¦Ìmol/L)£¬ËùÒÔÈç¹ûÒª´ïµ½Õý³£ÈËˮƽ£¬Ã¿Ìì¼ÁÁ¿±ØÐ볬¹ý3g£¬¸ù¾ÝVitCÒ©´úÒ©¶¯Ñ§Êý¾ÝºÍ³õ²½µÄ¼ÁÁ¿·´Ó¦Êý¾Ý£¬Marik[12]½ÌÊÚÌá³ö£¬ÓÃÓÚΣÖØÖ¢»¼Õߣ¬Ã¿ÈÕ¼ÁÁ¿Îª6g¡£
ÓÐÁ½ÏîСÐ͵ÄÁÙ´²Ñо¿£¬½«·Ç³£´óµÄ¼ÁÁ¿VitC(66mg/kg/h£¬-g/d)£¬³ÖÐø24hÓÃÓÚÉÕÉË»¼Õߣ¬Î´·¢ÏÖÓÐÃ÷ÏÔ²»Á¼·´Ó¦[13-14]¡£Ò²ÓÐÑо¿±íÃ÷£¬´ó¼ÁÁ¿VitCÒѱ»Ö¤Ã÷¿ÉÔö¼Ó¸Æ¡¢ÌúºÍÃÌÔÚÄòÒºÖеÄÅÅй£¬Òò´Ë¿ÉÄÜ»áÔö¼ÓÐγÉÉö½áʯµÄ·çÏÕ£»VitC´úлµÄ´úлÖÕ²úÎïÊDzÝËáÑΣ¬Òò´Ë³¤ÆÚ´ó¼ÁÁ¿¾²ÂöʹÓúó»áÌá¸ßÄòÒºÖвÝËáÑλòÄòËáˮƽ´Ó¶øµ¼Ö²ÝËáÑÎÉö²¡ÉõÖÁÉöË¥½ß[15]¡£µ«¶ÔûÓÐÉö¹¦ÄÜÒì³£µÄ²¡È˾²Âö×¢ÉäVitCÔò²»Ì«¿ÉÄܶÔÉö¹¦ÄÜÔì³ÉË𺦣¬¶ø¶Ô֮ǰÒѾ´æÔÚÉöÔà·½Ãæ¼²²¡µÄ²¡ÈËÓ¦½÷É÷ʹÓá£ÁíÓб¨µÀ´ó¼ÁÁ¿¸øÓèVitCÒýÆðÈÜѪµÄ°¸Àý[16]£¬ÆÏÌÑÌÇ-6-Á×ËáÍÑÇâø(G6PD)ȱ·¦Ö¢µÄ²¡ÈËÓ¦¸ÃÉ÷Óã¬Òò´Ë½¨Òé´ÓµÍ¼ÁÁ¿¿ªÊ¼Ê¹Óò¢ÇÒ»ºÂý¾²ÂöµÎ×¢£¬Í¬Ê±ÔÚÖÎÁÆÇ°¼ì²âG6PDȱ·¦Ö¢²¡È˵ÄG6PDˮƽ¡£
Ä¿Ç°ÉÐÎÞ¿É¿¿µÄÁÙ´²Ö¤¾Ý»òÖ¸ÄÏÃ÷È·ÍƼöµÄ¼ÁÁ¿£¬»¹Ðè¸ü¶à¾ßÓнϸ߼¶±ðµÄÑо¿Ö¤¾Ý¡£
5.VitCÄÜ·ñÓÃÓÚÔ¤·À²¡¶¾¸ÐȾÎÒÃǶ¼ÖªµÀ£¬ÆÕͨµÄ¸ÐðµÄ²¡Òò²¢²»ÊÇ×ÅÁ¹£¬¶øÊDz¡¶¾¸ÐȾ£¬Ö÷ÒªÊDZDz¡¶¾ºÍ¹Ú×´²¡¶¾£¬Ò»°ã²»ÐèÒªÖÎÁÆ¡£·»¼äÒ»Ö±Á÷´«¡°Î¬C·ÀÖθÐ𡱣¬ÔںܶàÀÏ°ÙÐÕÐÄÖиùÉîµÙ¹Ì¡£ÓÐȤµÄÊÇ£¬Õâ²¢·Ç³ö×ÔÒ½ÉúÖ®¿Ú£¬¶øÊÇÒ»¸ö»¯Ñ§¼Ò˵µÄ¡£Ä꣬һ±¾Ãû½Ð¡¶Î¬ÉúËØCÓëÆÕͨ¸Ðð¡·µÄÊé³ö°æÁË¡£Æä×÷ÕßÊÇÃÀ¹úÖøÃû»¯Ñ§¼ÒÀ³ÄÉ˹¡¤¿¨¶û¡¤±«ÁÖ¡£±«ÁÖÔÚÕâ±¾ÊéÖÐдµÀ£ºÃ¿Ìì·þÓÃ1¿Ë¸ü¶àµÄVitC£¬¿ÉÒÔ·ÀÖθÐð¡£Õâһй۵ãÁ¢ÂíÒýÆðºä¶¯£¬Êܵ½ºÜ¶à¶ÁÕßµÄ×·Åõ£¬µ«ÖÊÒɺͷ´¶ÔÉùÒ²½Óõà¶øÖÁ¡£ÃÀ¹úÎÀÉú»ù½ð»á¾Í¸æ½ë¶ÁÕߣº¡°Ã¿Ìì·þÓÃ0ºÁ¿ËÒÔÉÏVitCÄÜÔ¤·À¸ÐðµÄ˵·¨ÊÇÖ¤¾Ý²»³ä·ÖµÄ¡£¡±ÃÀ¹úҽѧлáÒ²·¢±íÉùÃ÷£º¡°VitC²»ÄÜÔ¤·À»òÖÎÁƸÐ𣡡±¡£ÌرðÊÇÔÚÄ꣬¶Ô29ÏîÏà¹ØÊÔÑé½øÐÐMETA·ÖÎö·¢ÏÖ[17]£º¶¨ÆÚ²¹³äVitC²¢²»ÄÜÏÔÖø½µµÍ¸ÐðµÄ·¢ÉúÂÊ¡£¶ÔÓÚÒѾ¸ÐðµÄÈËȺ£¬VitC»òÐíÄܼõÉÙ¸ÐðµÄ³ÖÐøʱ¼ä£¬µ«¶ÔÓÚÖÎÁÆЧ¹ûºÍʹÓõļÁÁ¿»¹ÐèÒª½øÒ»²½µÄÑо¿¡£
¿É¼û£¬¸ù¾ÝÄ¿Ç°µÄÑо¿£¬²¹³äάVitC¶ÔÓÚÎÒÃÇÆÕͨÈËÀ´Ëµ£¬²¢Ã»ÓÐÔ¤·À¸ÐðµÄ×÷Ó㬻òÐí¿ÉÒÔ¼õÉÙ¸ÐðµÄ³ÖÐøʱ¼ä¡£
×ܽáVitCÊÇÉúÎïÌåÖÐÖØÒªµÄ΢Á¿ÔªËØ£¬¶ÔÓÚά³ÖÕý³£ÉúÀí¹¦ÄÜÖÁ¹ØÖØÒª¡£Ä¿Ç°²¢ÎÞȨÍþµÄÖ¸ÄϺÍÖ¤¾ÝÍƼöÆäÓÃÓÚйڷÎÑ׸ÐȾ£¬ÐèÒªÏà¹ØµÄÁÙ´²ÊÔÑé½øÒ»²½ÑéÖ¤£¬¶ÔÓÚûÓл¼²¡µÄ»¼Õߣ¬×îºÃµÄVitCÀ´Ô´ÊÇÌìÈ»µÄ¹ûÊß¡£±ØÐëÌáÐѵÄÊÇ£¬ÖÎÁƼÁÁ¿µÄVitCÊÇ2-24g²»µÈ£¬¶ø×÷ΪÈÕ³£ÉÅʳÍƼö¼ÁÁ¿Ö»ÐèÒªmg£¬Èô¹ýÁ¿²¹³ä£¬³¤ÆÚ´óÁ¿·þÓã¬Ò²¿ÉÄÜ´øÀ´¸±×÷Óá£
²Î¿¼ÎÄÏ×
[1]¹ú¼ÒÎÀÉú½¡¿µÎ¯°ì¹«Ìü.¹ØÓÚÓ¡·¢ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÕïÁÆ·½°¸£¨ÊÔÐеÚÆ߰棩µÄ֪ͨ£¨¹úÎÀ°ìÒ½º¯[]ºÅ£©
[2]Áõ½¿,³Â¶ûÕ棬µÈ.ÖØÖ¢ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×»¼ÕßÓªÑøÖ§³ÖÖÎÁƵÄר¼Ò½¨Òé.ÖлªÖØ֢ҽѧµç×ÓÔÓÖ¾,,6(0):E.
[3]McNamaraR,DeaneAM,AnsteyJ,etal.Understandingtherationaleforparenteralascorbate(vitaminC)duringanacuteinflammatoryreaction:abiochemicalperspective[J].CritCareResusc,,20(3):-.
[4]ÉϺ£ÊÐÐÂÐ͹Ú×´²¡¶¾²¡ÁÙ´²¾ÈÖÎר¼Ò×é.ÉϺ£ÊйÚ×´²¡¶¾²¡×ۺϾÈÖÎר¼Ò¹²Ê¶[J/OL].Öлª´«È¾²¡ÔÓÖ¾,,38(-03-01)
[5]¹ã¶«Ê¡Ò©Ê¹ÜÀíÖÊÁ¿¿ØÖÆÖÐÐÄ.ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÁÙ´²ºÏÀíÓÃҩר¼Ò¹²Ê¶£¨µÚÈý°æ£©..03.06
[6]BorrelliE,Roux-LombardP,GrauGE,etal.Plasmaconcentrationsofcytokines,theirsolublereceptors,andantioxidantvitaminscanpredictthedevelopmentofmultipleorganfailureinpatientsatrisk[J].CritCareMed,,24(3):-.
[7]Evans-OldersR,EintrachtS,HofferLJ.MetabolicoriginofhypovitaminosisCinacutelyhospitalizedpatients[J].Nutrition,,26(11-12):-.
[8]Oudemans-vanStraatenHM,Spoelstra-deManAM,deWaardMC.VitaminCrevisited[J]CritCare,,18(4):
[9]ArmourJ£¬TyrolK£¬LidingtonD£¬eta1£®Ascorbatepreventsmicrovasculardysfunctionintheskeletalmuscleofthesepticrat[J]£®JApplPhysiol,1,90(3)£º-£®
[10]GaoYL,LuB,ZhaiJH,eta1.TheparenteralvitaminCimprovessepsisandsepsis-inducedmultipleorgandysfunctionsyndromeviapreventingcellularimmunosuppression[J]£®MediatotsInflamm£®,:£®
[11]WagnerSC£¬MarkosianB£¬AjiliN£¬eta1£®Intravenousascorbicacidasanadjuvanttointerleukin-2immunotherapy[J].JTranslMed£¬£¬12£º
[12]MarikPE,KhangooraV,RiveraR,HooperMH,CatravasJ.Hydrocortisone,vitaminC,andthiamineforthetreatmentofseveresepsisandsepticshock:aretrospectivebefore-afterstudy.Chest.;(6):¨C38.
[13]TanakaH,MatsudaT,MiyagantaniY,YukiokaT,MatsudaH,ShimazakiS:Reductionofresuscitationfluidvolumesinseverelyburnedpatientsusingascorbicacidadministration:arandomized,prospectivestudy.ArchSurg,:¨C.[14]KahnSA,BeersRJ,LentzCW:Resuscitationaftersevereburninjuryusinghigh-doseascorbicacid:aretrospectivereview.JBurnCareRes,32:¨C11
[15]ThomasLD£¬ElinderCG£¬TiseliusHG£¬eta1£®Ascorbieacidsupplementsandkidneystoneincidenceamongmen£ºaprospectivestudy[J]£®JAMAInternMed£¬£¬(5)£º¡ª£®
[16]OhnoS,OhnoY,SuzukiN,etal.High-dosevitaminC(ascorbicacid)therapyinthetreatmentofpatientswithadvancedcancer.AnticancerRes,9,29(3):.[17]HemilaH,ChalkerE.VitaminCforpreventingandtreatingthe